To analyze the prevalence of sleep problems in subjects with Chronic rhinosinusitis (CRS) and to determine whether the disease severity of CRS affects sleep quality. Methods: Questionnaires were sent to a random sample of 45 000 adults in four Swedish cities. Questions on CRS, asthma, allergic rhinitis, co-morbidities, tobacco use, educational level, and physical activity were included. CRS was defined according to the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) epidemiological criteria. The disease severity of CRS was defined by the number of reported CRS symptoms. Sleep quality was assessed using the Basic Nordic Sleep Questionnaire. Results: Of the 26 647 subjects, 2249 (8.4%) had CRS. Reported sleep problems were 50%-90% more common among subjects with CRS compared with those without or the total population. The prevalence of reported sleep problems increased in conjunction with the severity of CRS. After adjusting for gender, BMI, age, tobacco use, asthma, somatic diseases, physical activity level, and educational level, participants with four symptoms of CRS (compared with subjects without CRS symptoms) displayed a higher risk of snoring (adj. (4.71 [3.47-6.38]) and excessive daytime sleepiness (4.56 [3.36-6.18]). The addition of persistent allergic rhinitis to CRS further increased the risk of sleep problems. Conclusions: Sleep problems are highly prevalent among subjects with CRS. The disease severity of CRS negatively affects sleep quality.
INTRODUCTION
Chronic rhinosinusitis (CRS) is an inflammatory condition of the nose and sinuses, with a prevalence of 11%, according to a recent European survey. 1 The cardinal symptoms are nasal obstruction, nasal discharge, facial pain, and reduction or loss of smell. 2 CRS is associated with reduced quality of life and sleep complaints are common in this group of patients. 3 Few studies have investigated sleep in CRS and little is consequently known about sleep quality in CRS. Furthermore, the potential impact of disease severity on sleep quality has not been thoroughly investigated. In a recent study of 268 patients, 75% of CRS patients reported abnormal sleep quality, with poorer sleep seen in those with more severe sinus disease, as assessed by validated sleep-and disease-specific instruments. 4 Additional investigations, based on large populations and adequate assessments of sleep quality and CRS, are needed to clarify the relationship between CRS, disease severity, and sleep quality. The aim of the current large population-based study was to analyze the prevalence of sleep problems in individuals with CRS, utilizing the sleep quality tool, the Basic Nordic Sleep Questionnaire (BNSQ). 5 We also studied whether the disease severity of CRS had an influence on subjectively reported sleep. CRS was assessed according to the European Position Paper on Rhinosinusitis and nasal Polyps (EPOS) 2 epidemiological diagnostic criteria and disease severity was defined by the number of reported CRS symptoms.
MATERIALS AND METHODS

Study Population
The Global Allergy and Asthma European Network of Excellence (GA 2 LEN) consists of 22 centers in Europe. In 2008, the GA 2 LEN survey was conducted to collect information on asthma, allergy, and upper airway disease among adult Europeans. The Swedish questionnaire included questions on upper and lower respiratory disease, eczema, environmental and workplace exposure, insomnia, physical activity, and cardiovascular co-morbidity. It was sent to 45 000 randomly selected subjects aged 16-75 years in the four cities of Umeå, Uppsala, Stockholm, and Gothenburg. 6, 7 After three reminders, the response rate was 59.2%, equivalent to 26 647 subjects.
The study was approved by the Regional Ethical Review Board in Uppsala.
Definitions
"CRS" was defined according to the epidemiological criteria in the EPOS. 2 The subjects had to confirm the presence of two or more of the following symptoms: (1) nasal blockage/
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CRS disease severity" was defined according to the number of CRS symptoms the subjects confirmed (0-4), (1) nasal obstruction, (2) nasal discharge, (3) facial pain, and (4) reduction or loss of smell. The symptoms were added without any specific order. The EPOS definition of disease severity, based on the total severity visual analogue scale (VAS) score (0-10 cm), was not used since we did not have this information. 2 "Persistent allergic rhinitis (PER)" was defined according to the ARIA guidelines 8 with positive answers to the following three questions "Do you have any nasal allergies including hay fever?", "Have you ever suffered from nasal allergy for >4 days/ wk?" and "Was the duration >4 consecutive weeks?".
In the sleep-related questions the subjects were asked about the frequency of specific symptoms during the past months with the response options: (1) never or rarely (2) less than once a week (3) 1-2 times/wk (4) 3-5 times/wk and (5) almost every day or night.
"Snoring" was defined as "having loud and disturbing snoring" at least 3-5 times/wk. 9 "Insomnia symptoms" analyzed were: "difficulties inducing sleep (DIS)," "difficulties maintaining sleep (DMS)," "early morning awakening (EMA)," and "excessive daytime sleepiness (EDS)," for at least 3-5 times/wk according to the BNSQ. 5 The use of "Sleep medication" was defined as a positive answer to the question "Are you currently taking medication for sleeping problems?".
"Body mass index (BMI)" was calculated as self-reported body weight (kg) divided by height (m) squared (kg/m 2 ). "Current smoking" was defined as positive answers to both of the questions "Have you ever smoked one or more cigarettes a day for more than a year?" and "Have you smoked at all during the last month?".
"Current use of smokeless tobacco" was defined as positive answers to both of the questions "Have you ever used moist snuff on a daily basis for at least 6 months? and "Do you still use moist snuff?". "Current asthma" was defined as a positive answer to either of the two questions "Have you had an attack of asthma in the last 12 months?" or "Are you currently taking any medicine for asthma, including inhalers, aerosols or tablets?". "Education level" was categorized into 9-year compulsory school, high-school graduation, and academic degree.
"Co-morbidity" was defined as positive answers to any of the three questions "Are you currently taking medication for high blood pressure?/chronic obstructive pulmonary disorder?/diabetes?".
"Physical activity level" was assessed by the frequency of exercise resulting in breathlessness or sweating with the response options of every day, 4-6 times/wk, 2-3 times/wk, once/wk, and once/month or less.
Statistical Analyzes
Statistical analyzes were conducted using Stata 12.1 (Stata Corp, TX). Univariate analyzes were performed with the χ 2 test and the unpaired t test. Multiple logistic regression analyzes were used to calculate adjusted odds ratios (ORs) and confidence intervals for risk analyzes. A p value of <.05 was considered to be statistically significant.
RESULTS
The total study population consisted of 26 647 subjects, of which 2249 (8.4%) had CRS according to the study criteria. The population characteristics are presented in (Table 1) . Subjects with CRS had a higher mean BMI and were slightly younger than those without CRS. An academic degree was less common among CRS subjects and their physical activity level was generally lower. Current smoking and the use of smokeless tobacco were more prevalent among CRS subjects. Both PER and asthma were substantially more common among subjects with CRS. The co-morbidity of hypertension, chronic obstructive pulmonary disorder, and diabetes did not differ with respect to the CRS definition. The use of sleep medication was substantially higher among CRS subjects.
Nasal obstruction was the most common symptom (89.1%) among the CRS subjects, followed by nasal discharge (59.4%), facial pain (57.9%), and loss of smell (44.5%) (Figure 1 ).
The prevalence of sleep problems and related daytime symptoms was much higher among subjects with CRS compared with those without. More than half the participants who fulfilled the CRS criteria suffered from excessive daytime sleepiness. Analyzed sleep problems were 50%-90% more common among subjects with CRS.
As illustrated in Figure 2 , there was a gradual increase in the prevalence of sleep problems and related daytime symptoms in parallel with an increase in the number of CRS symptoms. After adjustment for possible confounders, significant associations were found between the number of CRS symptoms and the different sleep problems and related daytime symptoms ( Table 2 ). The highest OR in each analyzed category was seen when all four CRS symptoms were reported. Adjusting for sleep medication did not alter the results of the multiple regression analyzes (data not shown).
Since PER had a high prevalence among CRS subjects, we analyzed the impact of PER on sleep problems and related daytime symptoms by categorizing the subjects into four groups (1) no PER, no CRS (reference = 25 492), (2) PER but no CRS (n = 1949), (3) CRS but no PER (n = 1536) and (4) both PER and CRS (n = 582). In this model, the strongest association with sleep problems was found among subjects suffering from both PER and CRS (Table 3) .
DISCUSSION
In the present study, we found that the prevalence of sleep problems and daytime symptoms was substantially higher among subjects with CRS compared with the total population. Furthermore, there was a correlation between disease severity, defined as the number of reported CRS symptoms, and the degree of impairment of sleep quality. By analyzing subjects with both PER and CRS, an additional negative impact on sleep quality was found.
Several different mechanisms may be involved in the association between CRS and impaired sleep. The clear impact of the disease severity of CRS on sleep quality may reflect the inflammatory status of the sinonasal mucosa. In fact, several symptoms used to define CRS could reflect a higher degree of inflammation and the levels of the pro-inflammatory cytokines, IL-1β, and TNF-α, would then be upregulated correspondingly. Patients with CRS exhibit elevated levels of these cytokines, which have also been associated with sleep disturbance, fatigue, pain, depression, impaired cognition, and memory loss. 10, 11 Sleep disturbances in allergic rhinitis are also associated with several pro-inflammatory mediators and cytokines known to affect sleep quality negatively. 12, 13 This may explain why the CRS subjects also suffering from PER in our study experienced the poorest sleep quality of all subgroups.
Another more functional association between CRS and sleep relates to nasal obstruction, which was prevalent in 89.1% of subjects with CRS and was thereby the most important variable of disease severity in our study. Several studies have identified nasal obstruction as a contributory factor to both subjectively and objectively assessed sleep dysfunction.
In recent work by our group, self-reported nocturnal nasal obstruction in women, without any relationship to allergic rhinitis, had a negative impact on subjectively reported sleep-related problems and daytime symptoms but not on objective sleep variables. 14 We have also reported that subjective nasal obstruction is an independent risk factor for insomnia symptoms. 9 Other epidemiological studies indicate that nasal obstruction, due to allergic rhinitis or nasal polyposis, is an independent risk factor for sleep disturbances and daytime sleepiness. [15] [16] [17] Studies of medical and surgical treatments of nasal obstruction report improved subjective sleep quality, but improvements in objective sleep parameters remain to be proven. [18] [19] [20] [21] [22] The results of the present study further underline the crucial role played by nasal obstruction in sleep dysfunction. Additional research is needed to identify the mechanisms behind this relationship and to better understand the relative impact of the various inflammatory conditions and nasal obstruction that affect the upper airway and sleep.
Facial pain was present in 57.9% of the CRS subjects. Disturbed sleep is one of the most widespread co-morbid conditions in chronic pain patients. As many as 50%-77% of patients with orofacial pain and temporomandibular disorders report poor and reduced sleep quality. 23 Nasal discharge also had a high prevalence, 59.4%. This variable has not been studied as a separate entity in relation to sleep disturbance, but it has been studied as a co-morbid symptom of allergic rhinitis, consequently affecting sleep negatively. 16 Loss of smell had a prevalence of 44.5% among the CRS subjects. The impact on sleep of an impaired olfactory function has not been well studied either. In a study analyzing sleep quality and disease severity in patients with CRS, there was no difference in olfactory function between patients reporting good sleep quality compared with those reporting poor. 4 To summarize, each of the four CRS symptoms may contribute to an impairment in sleep quality. The strong correlation between the number of CRS symptoms and impaired sleep in the present study therefore seems plausible.
Cigarette smoking is also associated with CRS. 1, 24 Inflammatory changes in the nasal mucosa, reduced mucosal compliance, and subjective nasal obstruction are possible explanations of this association. [25] [26] [27] Considering that 22.7% of the CRS subjects were current cigarette smokers, compared with 13.1% of the subjects without CRS, cigarette smoking most probably contributed to the high prevalence of nasal obstruction seen in our CRS subjects. The ORs are adjusted for the same variables as in Table 2 . The use of sleep medication was more than twice as common among the CRS subjects compared with the subjects without CRS. This may be explained by the fact that "DIS," "DMS," and "EMA" were more prevalent among the CRS subjects, thus accounting for a higher use of medication.
The strength of the present study was the large size of our population-based material. The EPOS epidemiological symptom criteria were used to define CRS and an established sleep quality tool was used to analyze sleep. The population was gathered from similar types of urban area with surrounding suburbs, in four different regions, taking the geographical aspect into account. Furthermore, both men and women within a considerable age span were included.
One limitation of the study was that the questionnaire did not include questions on other sleep disorders such as obstructive sleep apnea syndrome (OSAS), making it a significant confounder in this study. Nor was there any assessment of the duration of the sleeping problems, or of the consequences, such as effects on quality of life and daytime performance. According to a recent review of 11 studies on the epidemiology of OSAS the estimated prevalence in a general population was 6% (range, 3%-18%) in men and 4% (range, 1%-17%) in women. 28 In an attempt to estimate the prevalence of OSAS in the present study we analyzed subjects who reported both snoring and excessive daytime sleepiness at least 3 times/wk. The prevalence of snoring and excessive daytime sleepiness was 6.2% in the total population and 15.5% among subjects with CRS (data not shown). It is therefore likely that part of the subjectively reported insomnia symptoms in the present study reflect sleep fragmentation secondary to a breathing disorder during sleep.
A further limitation of the study was the lack of assessment of depression and anxiety, two conditions associated with CRS, sleep problems, daytime sleepiness, and use of sleep medication. 29 Like other epidemiological studies, there is a risk of reporting bias, with an over-representation of symptomatic responders. The relatively low response rate in this study, 59.2%, could have contributed to this phenomenon, 30 although the effect may be limited. 31 This is the first epidemiological study of CRS and sleep quality. Our findings add new knowledge relating to the relationship between CRS and sleep quality. We conclude that the disease severity of CRS, defined as the number of symptoms, correlates with impaired sleep quality. The additive effect of a second inflammatory condition, PER, to CRS, confirms this finding. It is also evident that poor sleep quality is prevalent among CRS subjects. Clinically, this indicates that care should be taken to identify and treat CRS and concurrent upper airway diseases in patients suffering from sleep problems. Both medical and surgical treatments have proven successful in alleviating nasal obstruction and improving sleep quality and daytime sleepiness. [18] [19] [20] [21] Future studies should include objective measurements of CRS and sleep recordings to confirm the results of this study.
